Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A phase II study of ponatinib in cohorts of patients with lung cancer preselected using different candidate predictive biomarkers

 


A phase II study of ponatinib in cohorts of patients with lung cancer preselected using different candidate predictive biomarkers


Trial Focus

Lung Cancer

Objective

         This is a clinical trial of ponatinib that will be administered by mouth, which is investigational.

IRB Protocol #

13-2002

Trial Status

OPEN

Principle Investigator

ROSS CAMIDGE

Sponsor

ARIAD Pharmaceuticals, Inc.

Contact

BREANNA PRITCHARD at (720)848-0498 or BREANNA.PRITCHARD@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last as long as your disease does not worsen, you do not have severe side effects, and the study remains open. // Eligibility criteria include but are not limited to 18 years or older with lung cancer.Eligibility criteria include but are not limited to 18 years or older with lung cancer.